Jazz's $1B SCLC drug fails combo trial, quashing hopes of quick full approval

Lurbinectedin was looking like a great turnaround story for Spanish biotech PharmaMar. More than a year after the drug flopped in a Phase III ovarian cancer study, it hit the mark for overall response rate in small cell lung cancer, attracted Jazz Pharma to gamble on a $1 billion pact and landed an accelerated approval earlier this year.